T. Rowe Price Investment Management Inc. Has $75.40 Million Stock Holdings in Immatics (NASDAQ:IMTX)

T. Rowe Price Investment Management Inc. boosted its holdings in shares of Immatics (NASDAQ:IMTX) by 43.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 10,604,777 shares of the company’s stock after buying an additional 3,225,141 shares during the period. T. Rowe Price Investment Management Inc. owned approximately 0.09% of Immatics worth $75,400,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of IMTX. Guggenheim Capital LLC acquired a new position in shares of Immatics in the 4th quarter valued at about $101,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Immatics by 24.6% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company’s stock valued at $163,000 after buying an additional 4,477 shares during the period. Aristides Capital LLC acquired a new stake in shares of Immatics during the 4th quarter valued at $205,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Immatics during the 4th quarter valued at $211,000. Finally, Marshall Wace LLP purchased a new position in shares of Immatics during the 4th quarter valued at $409,000. 64.41% of the stock is owned by hedge funds and other institutional investors.

Immatics Stock Down 3.2 %

IMTX stock opened at $4.52 on Friday. The firm has a 50 day moving average of $4.42 and a two-hundred day moving average of $6.37. Immatics has a 12 month low of $3.30 and a 12 month high of $13.77. The company has a market capitalization of $549.41 million, a price-to-earnings ratio of -6.85 and a beta of 0.85.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings data on Thursday, March 27th. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.51. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. The firm had revenue of $15.67 million during the quarter, compared to analysts’ expectations of $16.16 million. On average, research analysts expect that Immatics will post -0.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Immatics in a research report on Tuesday, April 1st. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Immatics currently has an average rating of “Buy” and an average target price of $16.67.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.